Patents by Inventor Jonathan H. Davis
Jonathan H. Davis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11858979Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.Type: GrantFiled: February 16, 2021Date of Patent: January 2, 2024Assignee: Bristol-Meyers Squibb CompanyInventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
-
Publication number: 20230242617Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.Type: ApplicationFiled: August 16, 2022Publication date: August 3, 2023Inventors: Dasa LIPOVSEK, Jonathan H. DAVIS
-
Patent number: 11447538Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.Type: GrantFiled: January 10, 2020Date of Patent: September 20, 2022Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Dasa Lipovsek, Jonathan H. Davis
-
Publication number: 20220204589Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.Type: ApplicationFiled: November 16, 2021Publication date: June 30, 2022Inventors: Tracy S. MITCHELL, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan H. Davis, David Fabrizio
-
Patent number: 11203630Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.Type: GrantFiled: August 23, 2019Date of Patent: December 21, 2021Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan H. Davis, David Fabrizio
-
Publication number: 20210277089Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.Type: ApplicationFiled: February 16, 2021Publication date: September 9, 2021Inventors: Ray CAMPHAUSEN, Jonathan H. DAVIS, Sharon T. CLOAD, Fabienne M. DENHEZ, Amna SAEED-KOTHE, Dasa LIPOVSEK, Ching-Hsiung Frederick LO, Chee Meng LOW, Bowman MIAO, Tracy S. MITCHELL, Rex A. PARKER, Ginger C. RAKESTRAW, Katie A. RUSSO, Doree F. SITKOFF
-
Patent number: 10947297Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.Type: GrantFiled: November 21, 2017Date of Patent: March 16, 2021Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
-
Publication number: 20200247873Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.Type: ApplicationFiled: January 10, 2020Publication date: August 6, 2020Inventors: Dasa Lipovsek, Jonathan H. Davis
-
Publication number: 20190211079Abstract: The present invention provides an engineered multidomain protein including at least two nonidentical engineered domains, each of which contains a protein-protein interaction interface containing amino acid sequence segments derived from two or more existing homologous parent domains, thereby conferring on the engineered domains assembly specificities distinct from assembly specificities of the parent domains. In particular, the engineered domains form heterodimers with one another preferentially over forming homodimers. Methods of designing and using the engineered proteins are also included.Type: ApplicationFiled: December 12, 2018Publication date: July 11, 2019Inventors: Jonathan H. Davis, James S. Huston
-
Publication number: 20180201665Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.Type: ApplicationFiled: November 21, 2017Publication date: July 19, 2018Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
-
Patent number: 9856309Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.Type: GrantFiled: December 2, 2015Date of Patent: January 2, 2018Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
-
Publication number: 20170145078Abstract: The present invention provides an engineered multidomain protein including at least two nonidentical engineered domains, each of which contains a protein-protein interaction interface containing amino acid sequence segments derived from two or more existing homologous parent domains, thereby conferring on the engineered domains assembly specificities distinct from assembly specificities of the parent domains. In particular, the engineered domains form heterodimers with one another preferentially over forming homodimers. Methods of designing and using the engineered proteins are also included.Type: ApplicationFiled: November 28, 2016Publication date: May 25, 2017Inventors: Jonathan H. Davis, James S. Huston
-
Patent number: 9505848Abstract: The present invention provides an engineered multidomain protein including at least two nonidentical engineered domains, each of which contains a protein-protein interaction interface containing amino acid sequence segments derived from two or more existing homologous parent domains, thereby conferring on the engineered domains assembly specificities distinct from assembly specificities of the parent domains. In particular, the engineered domains form heterodimers with one another preferentially over forming homodimers. Methods of designing and using the engineered proteins are also included.Type: GrantFiled: October 3, 2014Date of Patent: November 29, 2016Assignee: Merck Patent GmbHInventors: Jonathan H. Davis, James S. Huston
-
Publication number: 20160159883Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.Type: ApplicationFiled: December 2, 2015Publication date: June 9, 2016Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
-
Patent number: 9234027Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.Type: GrantFiled: March 15, 2013Date of Patent: January 12, 2016Assignee: Bristol-Myers Squibb CompanyInventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
-
Publication number: 20150361159Abstract: Fibronectin type III (10Fn3) binding domains having novel designs are provided. Also provided are 10Fn3 domains having combinations of modified regions that can bind to a desired target.Type: ApplicationFiled: January 30, 2014Publication date: December 17, 2015Inventors: Dasa LIPOVSEK, Jonathan H. Davis
-
Publication number: 20150104865Abstract: The present invention provides an engineered multidomain protein including at least two nonidentical engineered domains, each of which contains a protein-protein interaction interface containing amino acid sequence segments derived from two or more existing homologous parent domains, thereby conferring on the engineered domains assembly specificities distinct from assembly specificities of the parent domains. In particular, the engineered domains form heterodimers with one another preferentially over forming homodimers. Methods of designing and using the engineered proteins are also included.Type: ApplicationFiled: October 3, 2014Publication date: April 16, 2015Inventors: Jonathan H. Davis, James S. Huston
-
Patent number: 8871912Abstract: The present invention provides an engineered multidomain protein including at least two nonidentical engineered domains, each of which contains a protein-protein interaction interface containing amino acid sequence segments derived from two or more existing homologous parent domains, thereby conferring on the engineered domains assembly specificities distinct from assembly specificities of the parent domains. In particular, the engineered domains form heterodimers with one another preferentially over forming homodimers. Methods of designing and using the engineered proteins are also included.Type: GrantFiled: March 23, 2007Date of Patent: October 28, 2014Assignee: Merck Patent GmbHInventors: Jonathan H. Davis, James S. Huston
-
Patent number: 8420098Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.Type: GrantFiled: April 13, 2011Date of Patent: April 16, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
-
Publication number: 20120094909Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.Type: ApplicationFiled: April 13, 2011Publication date: April 19, 2012Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff